Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway

Cancer Letters

Volumn 301, Issue 1, 2011, Pages 29-37

  Kim, Hyun Jung ^a   Kim, Sung Moo ^a   Park, Kyung Ran ^a   Jang, Hyeung Jin ^a   Na, Young Soon ^b   Ahn, Kyoo Seok ^a   Kim, Sung Hoon ^a   Ahn, Kwang Seok ^a  

^a Kyung Hee University   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Apoptosis; Bortezomib; Decursin; Multiple myeloma; STAT3

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; COUMARIN DERIVATIVE; CYCLIN D1; DECURSIN; INTERLEUKIN 6; JANUS KINASE 2; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL SPECIFICITY; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; METABOLIC INHIBITION; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; BENZOPYRANS; BORONIC ACIDS; BUTYRIC ACIDS; CASPASE 3; CELL LINE, TUMOR; CYCLIN D1; DNA; G1 PHASE; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MULTIPLE MYELOMA; PHOSPHORYLATION; PYRAZINES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 78650565629     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.11.002     Document Type: Article

References (39)

1. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004, 22:304-311.
2. Bonvini P., Zorzi E., Basso G., Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007, 21:838-842.
3. Oakervee H.E., Popat R., Curry N., Smith P., Morris C., Drake M., Agrawal S., Stec J., Schenkein D., Esseltine D.L., Cavenagh J.D. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 2005, 129:755-762.
4. Anargyrou K., Dimopoulos M.A., Sezer O., Terpos E. Novel anti-myeloma agents and angiogenesis. Leukemia Lymphoma 2008, 49:677-689.
5. Richardson P.G., Mitsiades C.S., Hideshima T., Anderson K.C. Novel biological therapies for the treatment of multiple myeloma. Best Pract. Res. Clin. Haematol. 2005, 18:619-634.
6. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner K., Pal A., Bornmann W.G., Chiao P.J., Huang P., Xiong H., Abbruzzese J.L., McConkey D.J. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006, 66:3773-3781.
7. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Dunner K., Huang P., Abbruzzese J.L., McConkey D.J. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 2005, 65:11658-11666.
8. Kardosh A., Golden E.B., Pyrko P., Uddin J., Hofman F.M., Chen T.C., Louie S.G., Petasis N.A., Schonthal A.H. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res. 2008, 68:843-851.
9. Aggarwal B.B. The past, present and future of multi-targeted cancer treatment "naturally" food for thought. Cancer Lett. 2008, 269:187-188.
10. Aggarwal B.B., Ichikawa H., Garodia P., Weerasinghe P., Sethi G., Bhatt I.D., Pandey M.K., Shishodia S., Nair M.G. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin. Ther. Targets 2006, 10:87-118.
11. Chi H.J. Studies on the components of Umbelliferae plants in Korea: pharmacological study of decursin, decursinol and nodakenin. Korean J. Pharmacol. 1970, 1:25-32.
12. Lee S., Lee Y.S., Jung S.H., Shin K.H., Kim B.K., Kang S.S. Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch. Pharm. Res. 2003, 26:727-730.
13. Konoshima M., Chi H.J., Hata K. Coumarins from the root of Angelica gigas Nakai. Chem. Pharm. Bull. (Tokyo) 1968, 16:1139-1140.
14. Ahn K.S., Sim W.S., Kim I.H. Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Planta Med. 1996, 62:7-9.
15. Kang S.Y., Lee K.Y., Park M.J., Kim Y.C., Markelonis G.J., Oh T.H. Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol. Learn. Mem. 2003, 79:11-18.
16. Yim D., Singh R.P., Agarwal C., Lee S., Chi H., Agarwal R. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005, 65:1035-1044.
17. Jiang C., Guo J., Wang Z., Xiao B., Lee H.J., Lee E.O., Kim S.H., Lu J. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Breast Cancer Res. 2007, 9:R77.
18. Kim W.J., Lee S.J., Choi Y.D., Moon S.K. Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation. Int. J. Mol. Med. 2010, 25:635-641.
19. Shiomi K., Hatano H., Morimoto H., Ui H., Sakamoto K., Kita K., Tomoda H., Lee E.W., Heo T.R., Kawagishi H., Omura S. Decursin and decursinol angelate selectively inhibit NADH-fumarate reductase of Ascaris suum. Planta Med. 2007, 73:1478-1481.
20. Lee H.J., Lee E.O., Lee J.H., Lee K.S., Kim K.H., Kim S.H., Lu J. In vivo anti-cancer activity of Korean Angelica gigas and its major pyranocoumarin decursin. Am. J. Chin. Med. 2009, 37:127-142.
21. Jung M.H., Lee S.H., Ahn E.M., Lee Y.M. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 2009, 30:655-661.
22. Son S.H., Kim M.J., Chung W.Y., Son J.A., Kim Y.S., Kim Y.C., Kang S.S., Lee S.K., Park K.K. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. Cancer Lett. 2009, 280:86-92.
23. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., Sung B., Ichikawa H. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. NY Acad. Sci. 2006, 1091:151-169.
24. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koca C., Dey S., Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann. NY Acad. Sci. 2009, 1171:59-76.
25. Shuai K., Stark G.R., Kerr I.M., Darnell J.E. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993, 261:1744-1746.
26. Ahn K.S., Sethi G., Sung B., Goel A., Ralhan R., Aggarwal B.B. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT 3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res. 2008, 68:4406-4415.
27. Pandey M.K., Sung B., Ahn K.S., Aggarwal B.B. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT 3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol. Pharmacol. 2009, 75:525-533.
28. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets 2008, 12:463-476.
29. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
30. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
31. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Woo M., Soengas M.S., Elia A., de la Pompa J.L., Kagi D., Khoo W., Potter J., Yoshida R., Kaufman S.A., Lowe S.W., Penninger J.M., Mak T.W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998, 94:339-352.
32. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
33. Kim J.H., Jeong J.H., Jeon S.T., Kim H., Ock J., Suk K., Kim S.I., Song K.S., Lee W.H. Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-kappaB activation in macrophages. Mol. Pharmacol. 2006, 69:1783-1790.
34. Ahn K.S., Noh E.J., Zhao H.L., Jung S.H., Kang S.S., Kim Y.S. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci. 2005, 76:2315-2328.
35. Carl V.S., Gautam J.K., Comeau L.D., Smith M.F. Role of endogenous IL-10 in LPS-induced STAT 3 activation and IL-1 receptor antagonist gene expression. J. Leukocyte Biol. 2004, 76:735-742.
36. Yu Z., Zhang W., Kone B.C. Signal transducers and activators of transcription 3 (STAT 3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem. J. 2002, 367:97-105.
37. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
38. Danial N.N., Pernis A., Rothman P.B. Jak-STAT signaling induced by the v-abl oncogene. Science 1995, 269:1875-1877.
39. Simonian P.L., Grillot D.A., Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997, 90:1208-1216.